Spots Global Cancer Trial Database for Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
Official Title: A Phase IIB, Open Label, Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies, Scheduled to Receive Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy
Study ID: NCT05013099
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate whether zirconium Zr 89 crefmirlimab berdoxam (other names 89Zr-crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C) PET/CT can predict the response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
CARTI Cancer Center, Little Rock, Arkansas, United States
City of Hope, Duarte, California, United States
Providence Saint John's Cancer Institute, Santa Monica, California, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
UT Southwestern Medical Center, Dallas, Texas, United States
University of Washington, Seattle, Washington, United States
Macquarie University Hospital, Macquarie Park, New South Wales, Australia
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Olivia Newton-John Cancer Research Insititute, Heidelberg, Victoria, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
University Hospitals Leuven, Leuven, , Belgium
Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
Leiden University Medical Center, Leiden, , Netherlands
Lausanne University Hospital, Lausanne, , Switzerland
Northern Centre for Cancer Care and Newcastle University, Newcastle Upon Tyne, , United Kingdom
Contact Details
Name: Kim Margolin, MD
Affiliation: Providence Saint John's Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
